Lilly(Eli) & Co

NYSE:LLY   9:36:27 AM EDT
246.71
+3.58 (+1.47%)
Products, Strategic Combinations, Other Pre-Announcement

Lilly And Regor Therapeutics Group Enter Into Strategic Collaboration To Discover And Develop Novel Therapies For Metabolic Disorders

Published: 12/10/2021 11:41 GMT
Lilly(Eli) & Co (LLY) - Lilly and Regor Therapeutics Group Enter Into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders.
Eli Lilly - Lilly Will Have a License to Select Regor Intellectual Property With an Option to Extend License.
Eli Lilly - Lilly Will Be Responsible for Clinical Development, Manufacturing and Commercialization Worldwide.
Eli Lilly - Company is Also Eligible to Receive Up to $1.5 Billion in Potential Payments Based on Achievement of Prespecified Preclinical.
Eli Lilly - Regor Will Receive an Upfront Payment of Up to $50 Million, Which Partially Includes an Equity Investment by Lilly in Regor.
Eli Lilly - There Will Be No Change to Lilly's 2021 Non-GAAP Earnings per Share Guidance As a Result of This Transaction.
Eli Lilly - Regor Will Receive an Upfront Payment of Up to $50 Million.
Eli Lilly - Eligible to Receive Up to $1.5 Billion in Potential Payments Based on Achievement of Milestones.